NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company focused on discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. The company utilizes its proprietary FIND-IO™ platform to identify novel cell surface molecular targets and biological pathways that mediate immune responses, aiming to restore normal immune function in patients who do not respond to current therapies. The company's strategy emphasizes the development of differentiated mechanisms of action, including Antibody-Drug Conjugates (ADCs) and fusion proteins. NextCure is currently advancing a pipeline of clinical candidates targeting various solid tumors and hematologic malignancies, often in combination with established checkpoint inhibitors like pembrolizumab.